Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.67 |
| ▸ | KIT | P10721 | 3/20 | 0.61 |
| ▸ | SRC | P12931 | 3/20 | 0.61 |
| ▸ | FLT3 | P36888 | 3/20 | 0.61 |
| ▸ | INSR | P06213 | 2/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.49 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892297 | 0.92 | CSF1R (0.60) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4891982 | 0.92 | CSF1R (0.57) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4583634 | 0.91 | CSF1R (0.81) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4893064 | 0.91 | CSF1R (0.66) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4587773 | 0.91 | CSF1R (0.57) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4890512 | 0.90 | CSF1R (0.61) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4892602 | 0.85 | CSF1R (0.65) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4889583 | 0.85 | CSF1R (0.73) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4573110 | 0.84 | CSF1R (0.75) | CSF1RKITSRCFLT3INSR | |
| SCHEMBL4573239 | 0.84 | CSF1R (0.73) | CSF1RKITSRCFLT3INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | FLT3, FES, ALK | CSF1R 430/4885KIT 363/4885SRC 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.